## FORM 4

obligations may continue. See

Check this box if no longer subject to Section 16. Form 4 or Form 5

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL 3235-0287 len

0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	
	Estimated average burd	
Filed annual to Oction 40(s) of the Octomities Functions Act of 4004	hours per response:	

Instruction 1(I	o).		Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940				
1. Name and Address of Reporting Person* <u>Miller Steve</u> (Last) (First) (Middle) 355 ALHAMBRA CIRCLE, SUITE 1250		(Middle)	2. Issuer Name and Ticker or Trading Symbol <u>CATALYST PHARMACEUTICALS, INC.</u> [CPRX]     3. Date of Earliest Transaction (Month/Day/Year)     12/22/2020		tionship of Reporting Pe all applicable) Director Officer (give title below) Chief Operatin	10% Owner Other (specify below)	
(Street) CORAL GABLES (City)	FL (State)	33134 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	ridual or Joint/Group Fili Form filed by One Re Form filed by More th Person	porting Person	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.				5. Amount of Securities Beneficially Owned Following	(D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common stock, par value \$0.001 per share	12/22/2020		М		20,000	Α	(1)	677,687	D	

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 3. Transaction Date (Month/Day/Year) 6. Date Exercisable and Expiration Date (Month/Day/Year) 1. Title of Derivative 3A. Deemed Execution Date, 7. Title and Amount of Securities 8. Price of Derivative 9. Number of derivative 11. Nature of Indirect 5. Number 10. Conversion Transaction Ownership Derivative Underlying Derivative Security Security (Instr. 3) or Exercise if any (Month/Day/Year) Code (Instr. Security (Instr. 5) Securities Form: Beneficial Direct (D) 8) Price of Securities Beneficially Ownership Acquired (A) or Disposed Derivative (Instr. 3 and 4) Owned Following or Indirect (I) (Instr. 4) (Instr. 4) Security Reported Transaction(s) (Instr. 4) of (D) (Instr 3, 4 and 5) Amount or Number Expiration Date Date Shares v (A) (D) Exercisable Title Code Restricted Common (1) 12/22/2020 20,000 (2) (3) 20,000 1,315,000 D Stock Units A \$<mark>0</mark> Stock

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.

2. Derivative securities vest in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022.

3. Shares of common stock will be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on December 22, 2020.

/s/ Steve Miller \*\* Signature of Reporting Person 12/23/2020

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.